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ABSTRACT 
 
Following recent regional court decisions on the 
infringement of second medical use patent claims, the 
German concept of manifest arrangement—previously 
believed to provide a safe harbor for generic pharmaceutical 
companies as long as they skinny-labeled their products—
may be subject to a new interpretation. The German 
decisions are part of a Europe wide series of decisions on 
the same or similar subject matter and prove to be patent 
owner friendly.1 
 
 
 
 
                                                                                                             
* Dr. Matthias Zigann, Presiding Judge, Munich Regional Court I, 7th (Patent) 
Division, Munich, Germany. 
1 Denmark; http://kluwerpatentblog.com/2015/08/06/pregabalin-second-
medical-use-claims-construction-in-denmark/; England & Wales: Generics 
(UK) Ltd (t/a Mylan) v Warner-Lambert Company LLC [2015] EWHC 
2548 (Pat); France: http://ipkitten.blogspot.de/2015/11/vive-la-difference-
no-need-for.html Spain: 
http://www.internationallawoffice.com/Newsletters/Intellectual-
Property/Spain/Grau-Angulo/Court-dismisses-preliminary-injunction-
application-in-pregabalin-patent-case#decision;  The Netherlands: Novartis 
AG v Sun Pharmaceutical Industries (Europe) BV C/09/460540 / KG ZA; 
Warner-Lambert Company LLC v. the State of The Netherlands (Dutch 
Medicines Evaluation Board), District Court of The Hague, The 
Netherlands, 15 January 2016, Case file number: C/09/498943 / KG ZA 15-
1656. 
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INTRODUCTION 
 
In 2000, Swiss-type second medical use patent claims (e.g. “use 
of x for the manufacture of a medicament to cure illness y”)2 were 
invented to overcome or circumvent the exclusion from patentability 
of methods to cure the human body as laid down in the original Art. 
52 (4) EPC.3 Since then, discussion has arisen about the new scope 
of protection for such claims. Particular attention has gone to 
distinguishing competitive legal behavior—which could be aimed at 
the production, distribution, and application of a medicament 
intended to cure the first now-unpatented indication—from illegal 
behavior aimed at the production, distribution, and application of the 
same medicament to cure a second patented indication.4 
 Recently confirmed5 decisions6 by the Federal Court of 
Justice found that the manifest arrangement of a medicament for the 
second medical use already constitutes a second medical use. In 
answer, the lower infringement courts granted injunctions against 
competitors for direct patent infringement, pursuant to Sec. 9 
                                                                                                             
2 According to legal advice given by the Swiss Patent Office in May 1984, these 
are called Swiss Type Claims. 
3 Revision entered into force on 13 December 2007. 
4Königer/Kompter/Ludwig/Lunze/Prinz zu Waldeck und Pyrmont/ 
Schüssler/Wiegeleben GRUR Int. 2014, 906. 
5 Federal Court of Justice IBRR3 2016, 1909 – Pemetrexed [#83-88]. The 
Federal Court of Justice has indicated in that decision that a Swiss-type 
claim may provide the same purpose limited substance protection as a 
purpose limited substance claim does. The finding is however not final as 
the case has been sent back to the lower court for further consideration.  
6 Federal Court of Justice GRUR 1983, 729, 730/731– Hydropyridin; GRUR 
2001, 730, 730/731 – Trigonellin. 
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German Patent Act,7 if they manifestly arranged their product for 
the second medical use.8 Processes such as making into a confection 
ready-to-use preparation, dosage, label instructions (as closely 
linked to the manufacturing process) or otherwise arranging the 
product were found to be manifest arrangements, especially if 
designed for a second medical use. The question as to whether the 
manifestly arranged product was later in fact used for the second 
indication was of no importance.9 However, other activities—like 
general announcements in marketing materials, flyers, and 
advertisements or indications given by sales people—were held 
insufficient to constitute a manifest arrangement, as they were found 
to be not related closely enough to the product or package.10 The so-
called “skinny labeling” proved to be a way for the competitor to 
avoid allegations of direct patent infringement, even when the 
product was later used for its second indication11. As a result, patent 
owners raised fewer allegations of indirect patent infringement 
                                                                                                             
7 A patent shall have the effect that the patentee alone shall be authorized to use 
the patented invention. A person not having the consent of the patentee shall 
be prohibited 1. from making, offering, putting on the market or using a 
product which is the subject matter of the patent or importing or stocking 
the product for such purposes; 2. from using a process which is the subject 
matter of the patent or, when he knows or it is obvious from the 
circumstances that the use of the process is prohibited without the consent 
of the patentee, from offering the process for use within the territory to 
which this Law applies; 3. from offering, putting on the market, using or 
importing or stocking for such purposes the product obtained directly by a 
process which is the subject matter of the patent. 
8 Regional Court Düsseldorf GRUR-RR 2004, 193 – Ribavirin. 
9 Regional Court Düsseldorf GRUR-RR 2004, 193 – Ribavirin. 
10 Regional Court Düsseldorf –Ribavirin“, 24 February 2004 – 4a O 12/03, 
BeckRS 2004, 05148; Higher Regional Court Düsseldorf - “Cistus 
Incanus”, 31 January 2013 – I-2 U 53/11, BeckRS 2013, 03824; Higher 
Regional Court Düsseldorf - “Cistus Incanus”, 31 January 2013 – I-2 U 
54/11; BeckRS 2013, 11782; Regional Court Düsseldorf - “Chronische 
Hepatitis C”, 14 March 2013 – 4a O 145/12, Düsseldorfer Entscheidungen 
No. 2011. 
11 Higher Regional Court Düsseldorf BeckRS 2013, 11782 – Cistus Incanus; 
Regional Court Düsseldorf, Case No. 4 a O 145/12, decision of 14 March 
2013 –- Chronische Hepatitis C. 
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pursuant to Sec. 10 of the German Patent Act.12 Notably, this was 
because patent owners could not prove that the competitor knew that 
the customer was inclined to use the product for the second 
indication and not the first. 
 
 I.  THE HAMBURG REGIONAL COURT`S DECISION 
 
However, recent decisions by the Hamburg Regional Court13 in 
five parallel preliminary proceedings may have taken away the “safe 
harbor” of skinny labeling, particularly in the context of rebate 
agreements.  
 
A.  Factual Circumstances 
 
The second medical use patent in suit covered the use of 
Pregabalin for the preparation of a pharmaceutical composition for 
treating pain. The defendants, pharmaceutical companies, produced 
a medicament for the (patent-free) first medical uses of 
Pregabalin—namely, to treat epilepsy and generalized anxiety 
disorder.14 The labels did not mention pain as an indication and there 
was no advertisement or marketing activity in that direction. After  
tender procedures for providing Pregabalin in large quantities to 
public health insurers, the defendants entered into  rebate 
agreements with these health insurers. The rebate agreements were 
silent on the intended medical uses; in particular, they did not carve 
                                                                                                             
12 A patent shall have the further effect that a person not having the consent of 
the patentee shall be prohibited from supplying or offering to supply within 
the territory to which this Law applies a person, other than a person entitled 
to exploit the patented invention, with means relating to an essential 
element of such invention for exploiting the invention, where such person 
knows or it is obvious from the circumstances that such means are suitable 
and intended for exploiting the invention. 
13 2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330; 4 
out auf 5 parallel preliminary injunctions have become final. One appeal is 
still pending, an oral hearing (case no. 3 U 91/15) scheduled for July 28, 
2016 has been postponed to February 2017 to await the outcome of pending 
nullity proceedings. 
14 2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330; 
appeal is pending, an oral hearing is scheduled for July 28, 2016. 
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out the use of Pregabalin to be provided to treat pain.15  
Sec. 130a (8) of the German Social Law Book V provides for 
the possibility of health insurers entering into such rebate 
agreements with pharmaceutical companies. Sec. 129 (1) of that law 
provides that pharmacists, in order to not endanger their 
reimbursement by the health insurer, must take account of these 
rebate agreements. The section puts pharmacists under the 
obligation to dispense the cheapest drug to an insured patient unless 
the doctor`s prescription explicitly orders to provide a specific brand 
by striking out the “aut idem” field. This is referred to as the 
“automatic substitution rule.” By budget control, doctors on the 
other hand are motivated to leave the “aut idem” field on their 
prescriptions and, consequently, allow substitution.16 
 
B.  Decision and Reasoning 
 
The Regional Court of Hamburg found that the defendants 
indirectly infringed the second medical use claim by signing the 
rebate agreement without explicitly carving out the use to treat pain 
and by providing Pregabalin to pharmacies in the course of the 
agreement.17 With respect to the regulatory environment, it was 
found to be manifestly clear that the defendants provided the 
Pregabalin for a later use to treat pain.  
As shown above other German courts have limited the use of a 
Swiss-type second medical use claim to a manifest arrangement that 
can be closely linked to the confectioning of the product or its 
packaging. Though  the Regional Court raised the question whether 
the concept of manifest arrangement is to be applied to the test of 
indirect infringement at all. However, the court left this question 
open by finding that the products subject to the rebate agreements 
were already confectioned and ready to be used for the treatment of 
pain. The purpose, the court claimed, was added by the pharmacist 
                                                                                                             
15 2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330; 
appeal is pending, an oral hearing is scheduled for July 28, 2016. 
16 2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330; 
appeal is pending, an oral hearing is scheduled for July 28, 2016. 
17 2 April 2015 – 327 O 67/15; BeckRS 2015, 08240; GRUR-RR 2015, 330; 
appeal is pending, an oral hearing is scheduled for July 28, 2016. 
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due to the automatic substitution; and it is obvious that the products 
offered and supplied under the rebate agreements will also be used 
in the patented indication to treat pain given the regulatory/social 
law environment. Carving-out and skinny labelling do not exclude 
indirect patent infringement if the rebate agreement is not limited to 
non-patented indications. The obligation under social law to 
dispense a substitute does not justify an infringement of the patent, 
as patent law requirements must be respected at all times.  
 
II.  OTHER DECISIONS 
 
In the context of the legal disputes which led to the Hamburg 
decision, the Hannover Social Court18 and the 2nd Federal 
Procurement Chamber of the Federal Cartel Office19 each granted 
preliminary injunctions against a health insurer based on public 
procurement law only, requiring the insurer not to enter into such 
rebate agreements and not to close such tenders respectively, as they 
are not in line with patent law. The details of the Hamburg patent 
law discussion were left basically untouched. Parallel patent 
litigation in other European courts showed mixed results20. 
 
 CONCLUSION 
 
Until the Regional Court of Hamburg`s decision, the belief 
existed that an indirect infringement of a Swiss-type second medical 
use claim encompassed actions such as providing a not-yet 
manifestly arranged drug to a customer in order to allow the 
customers to later manifestly arrange that drug for the second 
medical use. All intended activities by the customer aimed at the 
direct use of the drug rather than the manifest arrangement would 
not constitute indirect patent infringement by the manufacturer. If 
the Hamburg decisions are confirmed by the higher courts21, 
                                                                                                             
18 14 September 2015 – S 2 KR 374/15 ER. 
19 16 March 2015 – VK2 – 7/15; VPRRS 2015, 0147. 
20 See footnote no. 1. 
21 Which is however kind of unlikely due to the procedural circumstances as 4 
out of 5 parallel preliminary injunctions have by now become final as the 
defendants have accepted them. Only one appeal is still pending before the 
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however, this understanding of the concept of manifest arrangement 
would require modification. Currently, this understanding only 
provides a way to find direct patent infringement in a manifest 
arrangement, but no way to find indirect infringement in cases 
where the product itself or its packaging is neutral but other 
circumstances—as in the case decided in Hamburg—manifestly 
indicate the intention of the later use for the second indication. It has 
to be seen if the recent “Pemetrexed-decision22 shows a way out of 
this dilemma. The Federal Court of Justice has indicated in that 
decision that a Swiss-type claim may provide the same purpose 
limited substance protection as a purpose limited substance claim 
does. The finding is however not final as the case has been sent back 
to the lower court for further consideration.  
 
PRACTICE POINTERS 
 
• Skinny labeling and carving-out may no longer provide a safe 
harbor for competing pharmaceutical companies. 
• Competing pharmaceutical companies are strongly advised to 
enter into rebate agreements only if any patented second medical 
uses are explicitly carved out. 
• Health insurers are strongly advised to respect patent law in 
public tenders and rebate agreements, as social conventions no 
longer provide an excuse to disregard patent law. 
  
                                                                                                             
Hamburg Higher Regional Court (case no. 3 U 91/15). The oral hearing has 
been postponed from July 2016 to February 2017 to await the outcome of 
pending nullity proceedings. 
22 Federal Court of Justice IBRR3 2016, 1909 – Pemetrexed [#85-88]. 
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